What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Nov. 4, 2015, 4:08 PM
- PDL BioPharma (NASDAQ:PDLI): Q3 EPS of $0.42 misses by $0.19.
- Revenue of $124.6M (-24.3% Y/Y) misses by $40.2M.
- Shares +3.4%.
Nov. 3, 2015, 5:35 PM
- ACAS, ACLS, ACXM, AEL, AHT, ALB, ALR, ANDE, ARC, AREX, ARPI, ATO, AVG, AWAY, AWK, BGC, BKCC, BKD, BNFT, BOJA, BREW, BRKR, BWXT, CAA, CBPX, CCRN, CDI, CDXS, CF, CJES, CLR, CNAT, CODI, COHR, CPE, CSC, CSGS, CSII, CSLT, CTL, CVG, CVT, CXO, CXW, DCO, DOOR, DPM, DXCM, DYN, EGAN, ENVA, EOX, EPAM, EPM, EQC, ETE, ETP, EVAR, EVTC, EXAM, FB, FC, FEYE, FLT, FOE, FPRX, FRSH, FRT, FTD, FUEL, G, GDDY, GPOR, GTY, GUID, HABT, HASI, HDP, HIVE, HOLX, HR, HRTG, HUBS, IL, IO, JKHY, JONE, JRVR, KAI, KAR, KIM, KING, KND, KW, LADR, LCI, LDRH, LGCY, LHCG, LPSN, MATX, MB, MBI, MCHP, MCHX, MELI, MET, MHLD, MITT, MNTX, MOSY, MRIN, MRO, MTDR, MTRX, MUSA, MWA, MYRG, NLY, NNBR, NOG, NP, NWPX, OME, OSUR, PDLI, PE, PEIX, PFMT, PFSI, PGTI, PHH, PMT, POWR, PRA, PRI, PRU, PSEC, QCOM, QUOT, RDEN, RENT, RGR, RIG, RIGP, RJET, RLJ, RNR, RST, SBAC, SBY, SCSS, SD, SF, SGM, SLF, SPPI, SQNM, STR, SUN, SWM, SXL, TCAP, TEP, TROX, TS, TSE, TUMI, TWO, TXMD, UHAL, VEC, VVUS, WFM, WMGI, WPX, WRK, WSR, WTI, XENT, XNPT, XPO
Aug. 5, 2015, 4:05 PM
- PDL BioPharma (NASDAQ:PDLI): Q2 EPS of $0.47 misses by $0.05.
- Revenue of $138.07M (-15.2% Y/Y) beats by $0.32M.
May 6, 2015, 4:12 PM
- PDL BioPharma (NASDAQ:PDLI): Q1 EPS of $0.50 misses by $0.02.
- Revenue of $149.7M (+9.6% Y/Y) beats by $8.95M.
Feb. 23, 2015, 4:15 PM
- PDL BioPharma (NASDAQ:PDLI): Q4 EPS of $0.32 misses by $0.25.
- Revenue of $117.1M (+4.6% Y/Y) misses by $41.05M.
Feb. 22, 2015, 5:35 PM
Nov. 11, 2014, 9:20 AM
- PDL BioPharma (PDLI -0.6%) Q3 results: Revenues: $164.6M (+64.3%); G&A: $5.7M (-27.8%); Operating Income: $158.9M (+72.3%); Net Income: $102.2M (+81.9%); EPS: $0.61 (+69.4%); Quick Assets: $284.5M (+185.9%); CF Ops: $223.2M (+7.1%).
- Q4 2014 revenue guidance will be provided in December 2014.
Nov. 10, 2014, 4:07 PM
- PDL BioPharma (NASDAQ:PDLI): Q3 EPS of $0.61 beats by $0.05.
- Revenue of $164.6M (+64.3% Y/Y) misses by $0.5M.
Nov. 9, 2014, 5:35 PM
Nov. 3, 2014, 4:13 PM
- PDL BioPharma (PDLI) will report Q3 results on November 10 after the close. The conference call will begin at 4:30 pm ET.
- Consensus view is EPS of $0.56 on revenues of $165M.
Aug. 18, 2014, 4:24 PM
- PDL BioPharma (PDLI -1.6%) Q2 results: Revenues: $162.8M (+9.6%); Operating Expenses: $6.9M (+2.0%); Operating Income: $155.8M (+10.0%); Net Income: $92.1M (-1.7%); EPS: $0.52 (-16.1%); Quick Assets: $217.7M (+118.8%); CF Ops (1H): $146.2M (-10.0%).
- Revenue guidance for Q3 will be provided in September.
Aug. 18, 2014, 4:15 PM
- PDL BioPharma (NASDAQ:PDLI): Q2 EPS of $0.52 beats by $0.06.
- Revenue of $162.8M (+9.6% Y/Y) beats by $28.73M.
- Shares +1.93%.
Aug. 10, 2014, 5:35 PM
May 12, 2014, 4:24 PM
- PDL BioPharma (PDLI +0.4%) revenues: $139.7M (+52.2%); operating income: $123.2M (+45.5%); GAAP EPS: $0.44 (+22.2%); quick assets (ex-A/R): $337.6M (+239.3%); CF Ops: $91.8M (+73.5%).
- Q2 dividend of $0.15 payable June 12 to shareholders of record June 5.
- Management will provide Q2 revenue guidance in June. Consensus estimate for the quarter's top line is $131M, EPS: $0.45.
May 12, 2014, 4:05 PM
- PDL BioPharma (PDLI): Q1 EPS of $0.44 in-line.
- Revenue of $139.7M (+52.1% Y/Y) beats by $8.77M.
PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer & immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets & maximizing value of its patent.
Other News & PR